News Focus
News Focus
Post# of 257253
Next 10
Followers 77
Posts 4790
Boards Moderated 0
Alias Born 09/06/2003

Re: DewDiligence post# 151905

Wednesday, 11/07/2012 8:54:38 PM

Wednesday, November 07, 2012 8:54:38 PM

Post# of 257253
MNTA -

Is there a more promising biotech company with an enterprise value of $275M or less



Arguably many. Especially since Momenta's valuation has sooo many uncertainty factors in it and it is sooo far away in time:

a) Will the FDA actually allow substitutible FOBs? - Both in theory and in practice?

b) How long will it take to get it approved after submission? 8 years?

c) Will the drug still be viable after 8 years or will the market have been eroded due to non-sub generics. Or improved competitive products?

d) Will patents be enforceable? Or do trade secrets have to suffice - in which case competition will probably happen quicker?

e) Will Momenta ever move forward with any speed on the improved biologics? And if they do, what is the risk that the improvement is not enough?

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now